Advanced searches left 3/3

Inflammatory Bowel Disease - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 08 August 2022

* If you want to update the article please login/register

Digital Behavioral Interventions in Inflammatory Bowel Disease

Patients within Montefiore Medical Center's integrated health care system will be actively recruited and tested to find those with elevated psychological distress. Patients who qualify will be randomized to receive 8 weeks of iCBT or digital mood monitoring to assess the effects of iCBT on measures of psychological stability, HRQoL, and disease activity post-intervention.

Source link: https://clinicaltrials.gov/ct2/show/NCT04861597


A Controlled Trial of Yoga in Pediatric Inflammatory Bowel Disease (IBD)

Teenagers face additional challenges of mental and social adjustment as a result of a chronic illness with unpredictable and potentially embarrassing signs. Yoga may be able to reduce anxiety, provide a greater sense of bodily control, and raise QOL as an adjunct to traditional IBD therapy. The primary aim of this campaign is to see if a structured Yoga program, rather than standard medical therapy, raises HRQOL in pediatric patients with inflammatory bowel disease. Investigators will also investigate if the yoga program improves self-confidence, which is a person's belief about their ability to influence events that affect their lives. Patients will all be under their own authority and complete questionnaires at enrollment and at the end of the 12 week group yoga class sessions.

Source link: https://clinicaltrials.gov/ct2/show/NCT03338894


Improving the Quality of Care for Adults With Inflammatory Bowel Disease

The study collaborators will design, build, implement, and evaluate in up to 90 IBD healthcare centers the following four key elements of the IBD Learning Health System: 1 Acute Bowel Disease Learning Health System approach; 2 key information for physicians and physicians; and 4 multi-stakeholder collaborative networks for innovation and research.

Source link: https://clinicaltrials.gov/ct2/show/NCT02791854


Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease

Since these patient populations may have lower responses to vaccines, the toxicity of a candidate COVID-19 may be lower in immunosuppressed patients with IBD. Patients with IBD have varying vaccination responses compared to healthy controls, according to multiple studies. Although many patients have a normal vaccine reaction, those who have been administered with TNF agents or combination therapy are more likely to have a poor immune response. Patients with IBD will have normal immune responses to a COVID-19 vaccine, thereby, it is imperative to determine whether patients with IBD will have normal immune responses to a COVID-19 vaccine. This is a single center cross sectional clinical investigation of 260 patients with IBD who are receiving the COVID-19 vaccine as the gold standard of care for 260 patients with IBD. Determine the effects of systemic immunosuppression on sustained antibody COVID-19 levels in patients with IBD who have received the COVID-19 vaccine. Participants in the study can be either optional or at about 1-2 months after the third dose of the COVID-19 vaccine, which has been approved for patients with IBD. If participants received one booster, or 1-2 months after a 4th dose vaccine if participants received a second booster, the 12 month trip could be postponed by a 6 month post 3rd dose vaccine. Visit 3 will be the last blood draw for visitors who have not completed Visit 3 before July 2022, and will take place from July-October 2022 in the fall 2022 COVID-19 booster.

Source link: https://clinicaltrials.gov/ct2/show/NCT04818892


Inflammation and Intestinal Microbiota Modulation in Inflammatory Bowel Diseases

Preliminary results showed that butyrate therapy was able to improve the intestinal microbiota of patients with IBD and IBS-D after 12 weeks of treatment, as well as the changes of intestinal inflammation indexes, according to preliminary results. The analysis of intestinal microbiota will be carried out by taking a fecal sample and analyzing with metagenomics techniques.

Source link: https://clinicaltrials.gov/ct2/show/NCT04879914


Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

IBD is often described medically as abdominal pain, diarrhea, fever, weight loss, inability to thrive, and other related signs. It is thought that IBD disorders can be triggered by a combination of environmental, immune, genetic, and bacterial causes. Temporary anti-inflammatory drugs may ease the acute disease, followed by methotrexate or thiopurine to maintain remission states. Persecutors, absces, blocks, or cancer treatment, as well as cancer prevention, appear, are all significant. As there are more than Crohn's Disease and Ulcerative Colitis that seem to be related, there are no confirmed cases. Crohn's Disease alone appears to affect 3. 2 per 1000 people in Europe and North America alone. Typical symptoms may appear before actual diagnosis is made, with typical diagnoses occurring between 15 to 30 years old. Lead by abdominal pain signs and the recurrent periods of flare and remission. The AD-cSVF is a research group that provides guidance on the inflammatory mediators as well as inflammation modulation that favors chronic wound healing and avascular systems. The consequences of lesion sites remain unclear, but those involved in biocellular regenerative therapies have contributed to the healing and prevention of ulcerative skin lesions. Harvesting of autologous of adipose-derived tissue vascular fraction is a well-known source of microvascular stem/stromal cell elements with a well-documented growth factor and cytokine contributors. In cases of IBD, this report is intended to determine the safety and effectiveness of using autologous cellular therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT02952131


Milk-derived Gangliosides as Novel Anti-inflammatory Therapy for Inflammatory Bowel Disease

Objective 1: In patients with inflammatory bowel disease, dietary ganglioside therapy improves intestinal integrity, permeability, and systemic inflammation. BACKGROUND & SCOPE This is a pilot study that will examine dietary ganglioside's bioavailability in patients with mild-moderate IBD as determined by Crohn's disease activity index or Mayo Score. Low GI3 ganglioside in the intestinal mucosa is related to the breakdown of tight junction proteins. Increasing the GD3 content of the intestinal mucosa also reduces the degradation of tight junction proteins, improving the consistency of the brush border and improving intestinal permeability, which leads to loss of intestinal permeability. Researchers in progress from our company report that dietary ganglioside reduced the level of pro-inflammatory prostaglandin E2 in healthy human subjects and those with Crohn's disease. Also, daily intake of ganglioside was very effective in boosting the Crohn's disease activity index by an average of 43% over an eight-week study period. METHODS & PROCEDURE subject recruitment in Edmonton from the University of Alberta Hospital gastroenterology clinic would recruit healthy control subjects and patients with Crohn's disease and ulcerative colitis. Participants will be tested at baseline and week 2, 6, and 8 of the supplementation study. At weeks 0 and 8, a subject disease Activity Index or Mayo Score will be obtained. At study weeks 0 and 8, participants will perform non-invasive intestinal permeability testing at study weeks.

Source link: https://clinicaltrials.gov/ct2/show/NCT02139709


A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

This registry analysis will include volunteer pediatric patients with Crohn's Disease who have been treated with infliximab and over 2,000 pediatric patients with Crohn's Disease who have been treated with infliximab and approximately 2,000 pediatric patients with Crohn's Disease who have received therapies other than infliximab. Around 1,000 pediatric patients with Ulcerative Colitis or Indeterminant Colitis will be included in the study. The treating physicians will decide all patient medications for IBD in consultation with their patients based on normal clinical practice. Following infliximab treatment, certain patients may be eligible to participate in a subpoena that will assess blood levels of protein production that may occur after treatment. A small amount of additional blood may be obtained at the time of a routine blood draw that is part of a patient's regular medical care and may be ordered by a treating physician.

Source link: https://clinicaltrials.gov/ct2/show/NCT00606346

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions